The World Health Organization set goals in 2016 for reductions in prevalent and incident hepatitis C infection necessary to achieve elimination of HCV as a public health problem by 2030. Modeling demonstrates that global HCV control will require annual rates of cure that are consistently and significantly higher than new HCV infection rates. However, a recent study showed that nearly 60% of surveyed countries had the opposite- more HCV infections than cures. Therefore, control is unlikely to occur without improved focus on and success in reducing the number of new HCV infections. Risk factors for HCV infection vary globally, but together result in ~1.75 million new HCV infections annually worldwide. An effective preventative HCV vaccine could prevent transmission regardless of risk factors. While a highly effective vaccine could prevent infection altogether, a vaccine that increases the rate of HCV clearance and prevents chronic infection may be sufficient to reduce transmission and disease burden. Despite vaccine need, barriers to vaccine development remain, including limitations to HCV culture systems, viral diversity, limited models and at-risk populations for testing vaccines, and incomplete understanding of protective immune responses. On the positive side, there is evidence that protective immunity exists in populations at ongoing risk of infection. For those who have cleared initial infection and become reinfected, more rapid and effective control of viral replication with subsequent exposures compared to initial exposure supports that adaptive immunity develops and, while not sterilizing, that it protects against chronic disease. Decades of research have revealed that HCV-specific CD4+ helper T cells, CD8+ cytotoxic T cells, and antibodies are all important in mediating protection against persistent HCV infection. Vaccine strategies to induce all three adaptive immune responses are in development. Adjuvanted envelope or core protein and virally vectored non-structural antigen vaccines have advanced into healthy volunteers not at risk for HCV, with viral vectors encoding non-structural proteins the only vaccine strategy tested in at-risk individuals to date. Despite development challenges, a prophylactic vaccine is necessary for global HCV control. This talk will discuss the need for a vaccine, evidence that a vaccine to prevent chronic infection is possible, challenges to immunologic control of HCV, and the vaccine strategies tested to date.